A phase I/II dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC) in patients with prior treatment with 177Lu-PSMA.

被引：0
|
作者：
Nauseef, Jones T.
Sun, Michael Philip
Thomas, Charlene
Bissassar, Mahelia
Patel, Amie
Tan, Angela
Fernandez, Escarleth
Davidson, Zachary
Chamberlain, Tessa
Earle, Kara
Wunder, Rebecca
Castellanos, Sandra Huicochea
Gregos, Peter
Osborne, Joseph
Ballman, Karla V.
Molina, Ana M.
Sternberg, Cora N.
Nanus, David M.
Bander, Neil Harrison
Tagawa, Scott T.
机构：
[1] Weill Cornell Med, Div Hematol & Med Oncol, New York, NY USA
[2] Sandra & Edward Meyer Canc Ctr, New York, NY USA
[3] Weill Cornell Med, Div Hematol & Med Oncol, New York, NY USA
[4] Weill Cornell Med, New York, NY USA
[5] Weill Cornell Med Ctr, New York, NY USA
[6] Weill Cornell Med Coll, New York, NY USA
[7] Weill Cornell Med Mol Imaging & Therapeut, Dept Radiol, New York, NY USA
[8] NYP Brooklyn Methodist Hosp, Weill Cornell Med, Brooklyn, NY USA
[9] New York Presbyterian Hosp, Weill Cornell Med, New York, NY USA
[10] Cornell Univ, Weill Med Coll, NewYork Presbyterian Hosp, New York, NY USA
[11] Weill Cornell Med, Hematol Oncol, New York, NY USA
[12] NewYork Presbyterian Hosp, Div Hematol & Med Oncol, Weill Cornell Med, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS288
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase I/II dose-escalation study of fractionated and multiple dose 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).
    Sun, Michael
    Nauseef, Jones T.
    Lebenthal, Justin M.
    Niaz, Muhammad Junaid
    Singh, Sharon
    Chamberlain, Tessa A.
    Bissassar, Mahelia
    Patel, Amie
    Tan, Angela
    Vallabhajosula, Shankar
    Babich, John
    Christos, Paul J.
    Osborne, Joseph
    Molina, Ana M.
    Sternberg, Cora N.
    Nanus, David M.
    Bander, Neil Harrison
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [2] Phase I dose-escalation study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Vallabhajosula, Shankar
    Jhanwar, Yuliya
    Ballman, Karla V.
    Hackett, Amy
    Emmerich, Lauren
    Babich, John
    Sartor, A. Oliver
    Harshman, Lauren Christine
    Beltran, Himisha
    Molina, Ana M.
    Nanus, David M.
    Bander, Neil Harrison
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [3] Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC)
    Tagawa, Scott T.
    Osborne, Joseph
    Niaz, Muhammad Junaid
    Vallabhajosula, Shankar
    Vlachostergios, Panagiotis J.
    Thomas, Charlene
    Molina, Ana M.
    Sternberg, Cora N.
    Singh, Sharon
    Fernandez, Escarleth
    Babich, John
    Nanus, David M.
    Ballman, Karla V.
    Bander, Neil Harrison
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [4] Phase I/II study of 225Ac-J591 plus 177Lu-PSMA-I&T for progressive metastatic castration-resistant prostate cancer
    Nauseef, Jones T.
    Osborne, Joseph
    Gregos, Peter
    Thomas, Charlene
    Bissassar, Mahelia
    Singh, Sharon
    Patel, Amie
    Tan, Angela
    Naiz, Muhammad Obaid
    Zuloaga, Juana Martinez
    Chamberlain, Tessa
    Earle, Kara
    Wunder, Rebecca
    Nagar, Himanshu
    Molina, Ana M.
    Sternberg, Cora N.
    Nanus, David M.
    Bander, Neil Harrison
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Osborne, Joseph
    Fernandez, Escarleth
    Thomas, Charlene
    Niaz, Muhammad Junaid
    Ciriaco, Amy
    Vallabhajosula, Shankar
    Vlachostergios, Panagiotis J.
    Molina, Ana M.
    Sternberg, Cora N.
    Singh, Sharon
    Babich, John
    Nanus, David M.
    Ballman, Karla, V
    Bander, Neil Harrison
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Phase I/II dose-escalation trial of fractionated dose 177Lu-J591 plus 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Niaz, Muhammad Junaid
    Osborne, Joseph
    Vallabhajosula, Shankar
    Beltran, Himisha
    Harshman, Lauren Christine
    Nanus, David M.
    Molina, Ana M.
    Faltas, Bishoy Morris
    Hackett, Amy
    Gracey, Lauren
    Sreekumar, Jyothi
    Babich, John
    Ballman, Karla V.
    Bander, Neil Harrison
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [7] Phase I study of 225Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Sun, Michael
    Sartor, A. Oliver
    Thomas, Charlene
    Singh, Sharon
    Bissassar, Mahelia
    Fernandez, Escarleth
    Niaz, Muhammad Junaid
    Ho, Benedict
    Vallabhajosula, Shankar
    Babich, John
    Molina, Ana M.
    Sternberg, Cora N.
    Nanus, David M.
    Osborne, Joseph
    Bander, Neil Harrison
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Phase I dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)
    Tagawa, S. T.
    Vallabhajosula, S.
    Jhanwar, Y.
    Hackett, A.
    Oromendia, C.
    Naiz, M. J.
    Goldsmith, S. J.
    Nanus, D. M.
    Beltran, H.
    Molina, A. M.
    Faltas, B.
    Sreekumar, J.
    Babich, J.
    Ballman, K.
    Bander, N. H.
    ANNALS OF ONCOLOGY, 2018, 29
  • [9] PHASE I DOSE-ESCALATION TRIAL OF MULTIPLE AND FRACTIONATED-DOSE PSMA-TARGETED ALPHA RADIONUCLIDE (225AC-J591) FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Sun, Michael
    Nauseef, Jones
    Fajardo, Andres Ricaurte
    Davidson, Zachary
    Thomas, Joseph
    Ruder, Samuel
    Stangl-Kremser, Judith
    Castellanos, Sandra Huicochea
    Molina, Ana
    Sternberg, Cora
    Patel, Amie
    Yuan, Sarah
    Fernandez, Escarleth
    Fung, Edward
    Avlonitis, Vasilios
    O'Dwyer, Elisabeth
    Nanus, David
    Osborne, Joseph
    Bander, Neil
    Tagawa, Scott
    JOURNAL OF UROLOGY, 2024, 211 (05): : E67 - E68
  • [10] Phase I dose-escalation study of fractionated-dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Vallabhajosula, Shankar
    Batra, Jaspreet
    Christos, Paulj.
    Jhanwar, Yuliya
    Goldsmith, Stanley J.
    Nanus, David M.
    Beltran, Himisha
    Molina, Ana M.
    Faltas, Bishoy
    Hackett, Amy
    Sreekumar, Jyothi
    Babich, John
    Bander, Neil Harrison
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345